Taiho Ventures, launched two years ago with $50m in capital, has had its reserves expanded by a further $250m as Taiho Pharmaceuticals looks to enhance its open innovation work.
Taiho Ventures, the corporate venturing vehicle for Japan-based pharmaceutical company Taiho, increased the size of its investment pool from $50m to $300m earlier today.
Launched in May 2016, Taiho Ventures operates out of a US office situated in California, and focuses on early, preclinical-stage drug developers, particularly those working on cancer therapies which could utilise the resources of its parent company, a developer of oral anti-cancer treatments.
Taiho said it is providing the extra money not only to reinforce…
